MPO and diabetic kidney disease: Clinical research has demonstrated that alprostadil can reduce the expression of inflammatory factors such as myeloperoxidase (MPO), TNF-α, and IL-6 in the treatment of ischemia reperfusion injury, contrast nephropathy, and diabetic nephropathy etc. [24–27].